Gara Jalqabaatti › Kansarii Nasopharyngeal › Georgia
Qorannoo klinikaalii Kansarii Nasopharyngeal Georgia keessatti
Qorannoo 6 Kansarii Nasopharyngeal f Georgia keessatti hirmaatuu jiru.
Magaalota Georgia keessatti
Takkalaa qorannoo (Ingiliffa)
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- Emory University Hospital Midtown, Atlanta
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Emory University Hospital Midtown, Atlanta
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Namoota walitti qabaa jiraSadarkaa 2
Hanga umuriin 21 · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06064097Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ado-2026 · NCT06662058TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Bit-2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Gur-2026 · NCT06636734Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.